Anthera Pharmaceuticals


Anthera Pharmaceuticals, Inc. is an American biopharmaceutical company focused on developing and commercializing products to treat serious conditions associated with cystic fibrosis, inflammation and autoimmune diseases. Liprotamase, Anthera’s leading drug candidate which is being developed for exocrine pancreatic insufficiency is currently in Phase 3 clinical trials, and A-623 for the treatment of IgA nephropathy is currently in Phase 2 clinical trial.

Products

Blisibimod

July 2014, Anthera acquired Sollpura from Eli Lilly and Company. Sollpura is an investigational pancreatic enzyme replacement therapy that uses three biotechnology-derived digestive enzymes intended to treat patients with endocrine pancreatic insufficiency as a result of cystic fibrosis and other diseases.